Literature DB >> 8884148

Oral 9-cis-retinoic acid versus 13-cis-retinoic acid in acne therapy.

F Ott1, W Bollag, J M Geiger.   

Abstract

BACKGROUND: 9-cis-Retinoic acid (9-cis-RA) is as active as 13-cis-retinoic acid (13-cis-RA) in inhibiting the proliferation of cultured human sebocytes and in reducing the size of sebaceous glands of hamsters.
OBJECTIVE: Evaluate the anti-acne effect of 9-cis-RA compared to that of 13-cis-RA in a pilot study.
METHODS: Four young male patients with acne were treated in an open study consecutively with 9-cis-RA and 13-cis-RA given at similar doses.
RESULTS: No beneficial effects were observed with 9-cis-RA in any of the patients whereas all responded favorably to 13-cis-RA.
CONCLUSION: For the two retinoids tested, the anti-acne effect correlates with the sebosuppressive effect in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8884148     DOI: 10.1159/000246226

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  5 in total

1.  The use of isotretinoin in acne.

Authors:  Alison Layton
Journal:  Dermatoendocrinol       Date:  2009-05

Review 2.  Current use and future potential role of retinoids in dermatology.

Authors:  C E Orfanos; C C Zouboulis; B Almond-Roesler; C C Geilen
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

3.  Washout Period for Pregnancy Post Isotretinoin Therapy.

Authors:  Hina Jajoria; Venkataram Mysore
Journal:  Indian Dermatol Online J       Date:  2020-03-09

4.  Isotretinoin Induced Hyperlipidemia and Impact of Leptin Gene rs 7799039 Polymorphism in Safety of Acne Patients.

Authors:  Amal A Mohamed; Alshymaa Hassnine; Amr Elsayed; Mahmoud Montaser; Yasmeen Ismail; Ahmed El-Demery; Eman Sultan; Rania S Abdel Aziz; Eman Eldemiry; Radwa Hagag; Amal A El-Kholy; Eman Salah
Journal:  Pharmgenomics Pers Med       Date:  2021-12-24

5.  Evaluation of musculoskeletal adverse effects in patients on systemic isotretinoin treatment: A cross-sectional study.

Authors:  Emine Müge Acar; Senem Şaş; Fatmanur Aybala Koçak
Journal:  Arch Rheumatol       Date:  2021-12-24       Impact factor: 1.007

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.